Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vixarelimab in IPF and SSc-ILD
NCT05785624Phase 2Terminated
- Sponsor
- Genentech
- Start
- May 2023
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 19
01
Overview
Phase 2, randomised, double-blind trial of vixarelimab in idiopathic pulmonary fibrosis (IPF) and systemic sclerosis-associated interstitial lung disease (SSc-ILD), sponsored by Genentech. Primary endpoint: Absolute Change From Baseline in Forced Vital Capacity at 52 weeks. Started May 2023; status: terminated.
02
Drugs
vixarelimab
03
Conditions
idiopathic pulmonary fibrosis (IPF)systemic sclerosis-associated interstitial lung disease (SSc-ILD)
Beyond the preview
Go deeper on NCT05785624.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05785624.